Drug intelligence / Profile preview

dengue virus serotype-1 purified-inactivated vaccine

Development stage: Phase 1
Lead developer: Walter Reed Army Institute of Research
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

DENV-1 PIV is a monovalent, purified-inactivated vaccine against dengue virus serotype-1. It is adjuvanted with aluminum hydroxide (alum) to enhance immune response. The vaccine has been tested in Phase 1 clinical trials where it demonstrated an acceptable safety profile with minimal injection site and systemic reactions. By study day 42 (two weeks following the second vaccine dose), all volunteers in clinical trials developed serum-neutralizing antibodies against DENV-1. The vaccine is administered as two intramuscular injections on days 0 and 28.

Beyond the preview

Go deeper on dengue virus serotype-1 purified-inactivated vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dengue virus serotype-1 purified-inactivated vaccine.

Explore the full profile